Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients.
Thirty-seven primary renal transplant patients were enrolled in the early phase II study on kidney transplantation. All grafts survived during the follow-up period. However, 10 of the 37 patients were changed from FK 506 to conventional drugs, and 3 were treated concomitantly with azathioprine (AZA) or mizoribine (MZR) in the 3-month period of observation. After 3 months posttransplantation, an additional 10 patients were treated continuously with AZA or MZR. In addition, 3 were converted from FK 506 to conventional drugs. No additional conversion was observed after 4 months. Trough level monitoring was effective enough to regulate the FK 506 dosage. Nephrotoxicity and hyperglycemia were associated with a high trough level of FK 506 (whole blood, > 20 ng/ml).
D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood; D007564:Japan; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D019520:Living Donors; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011239:Prednisolone; D003404:Creatinine; D001379:Azathioprine; D016559:Tacrolimus